- COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS
-
Described herein are methods of treating a metabolic disorder in an individual in need thereof, comprising co-administering to the individual a therapeutically effective amount of an FXR modulator, and at least one second agent that is an CCR2/CCR5 antagonist, ASKl inhibitor, DPP-IV inhibitor, caspase protease inhibitor, SGLT2 inhibitor, acetyl-CoA carboxylase (ACC) inhibitor, diacyl glycerol acyltransferase-1 inhibitor, sodium -bile acid cotransporter-inhibitor, TLR-4 antagonist, PPAR alpha/delta agonist, or GLP-1 agonist, or a combination thereof.
- -
-
Paragraph 00708
(2017/12/29)
-
- FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE
-
Described herein are fused bicyclic compounds, compositions, and methods for their use for the treatment of disease.
- -
-
Paragraph 00619
(2016/07/27)
-